Baidu
map

JMGM:雷红星等抗癌药物分子机制研究获进展

2012-07-31 中国科学院北京基因组研究所 中国科学院北京基因组研究所

近日,中国科学院北京基因组研究所“百人计划”研究员雷红星及其研究组开展的“抗癌药物的分子机制研究”取得阶段性进展,其研究论文Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations,在Journal of Molecular Graphic

近日,中国科学院北京基因组研究所“百人计划”研究员雷红星及其研究组开展的“抗癌药物的分子机制研究”取得阶段性进展,其研究论文Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations,在Journal of Molecular Graphics and Modelling杂志发表。该文采用分子动力学的方法研究了阿霉素分子从自由状态到嵌入DNA碱基片段的动态过程,提出了一个新的药物分子插入机制(打开-插入机制),即插入过程是经外部结合后伴随着碱基对的打开(base-flipping)进行的。

阿霉素是一种临床上广泛使用的抗癌药物,它能有效治疗急性白血病、胃癌、肝癌等多种恶性肿瘤疾病。目前认为其作用机制是通过嵌入癌细胞的DNA碱基片段中,阻碍DNA的转录和复制,从而抑制肿瘤生长。但具体嵌入过程和分子机制还不是十分清楚。

为此,雷红星研究员及其科研团队从未结合的自由态(一段B型DNA片段和连个自有的阿霉素分子)出发,进行了全原子的分子动力学模拟。整个模拟过程验证了力场的可靠性,并以较高的空间和时间分辨率刻画出了结合过程中的结构和能量的动态变化规律。从模拟过程的轨迹中,研究人员观测到阿霉素分子与DNA结合的三种模式,包括一端结合、DNA小沟结合以及碱基之间结合。其中,结合到DNA小沟中是到最终插入状态的一个中间态,即“外部结合态”;结合到碱基之间要经历碱基对被打开(base-flipping)的过程。这种打开-插入的机制与之前提出的碱基对之间距离拉开再嵌入的机制有很大不同,拉开-插入机制需要使碱基对之间产生较大空间才可使药物分子插入,而打开-插入机制却不需要。

这一新机制的提出对于抗癌药物分子机制研究起到了积极的推动作用,为设计更有效的抗癌药物提供了理论依据。

doi:10.1016/j.jmgm.2012.05.006
PMC:
PMID:

Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations

Hongxing Leia, 1, , Xiaofeng Wanga, b, 1, Chun Wuc, ,

The intercalation mode between doxorubicin (an anticancer drug) and two 6 base-pair DNA model fragments (d(CGATCG)2 and d(CGTACG)2) have been well studied by X-ray crystallography and NMR experimental methods. Yet, the detailed intercalation pathway at molecular level remains elusive. In this study, we conducted molecular dynamics binding simulations of these two systems using AMBER DNA (parmbsc0) and drug (GAFF) force fields starting from the unbound state. We observed outside binding (minor groove binding or end-binding) in all six independent binding simulations (three for each DNA fragment), followed by the complete intercalation of a drug molecule in two simulations (one for each DNA fragment). First, our data directly supported that the minor groove binding is the dominant pre-intercalation step. Second, we observed that the opening and flipping of a local base pair (A3-T10 for d(CGATCG)2 and C1-G12 for d(CGTACG)2) in the two intercalation trajectories. This locally cooperative flipping-intercalation mechanism was different from the previously proposed rise-insertion mechanism by which the distance between two neighboring intact base pairs increases to create a space for the drug insertion. Third, our simulations provided the first set of data to support the applicability of the AMBER DNA and drug force fields in drug-DNA atomistic binding simulations. Implications on the kinetics pathway and drug action are also discussed.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056107, encodeId=0a0a205610e64, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Nov 22 18:51:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801178, encodeId=d56618011e855, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811285, encodeId=fb0a181128505, content=<a href='/topic/show?id=92ea8e68308' target=_blank style='color:#2F92EE;'>#药物分子机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87683, encryptionId=92ea8e68308, topicName=药物分子机制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 26 20:51:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308185, encodeId=3f55130818536, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314574, encodeId=9f4e13145e489, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056107, encodeId=0a0a205610e64, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Nov 22 18:51:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801178, encodeId=d56618011e855, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811285, encodeId=fb0a181128505, content=<a href='/topic/show?id=92ea8e68308' target=_blank style='color:#2F92EE;'>#药物分子机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87683, encryptionId=92ea8e68308, topicName=药物分子机制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 26 20:51:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308185, encodeId=3f55130818536, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314574, encodeId=9f4e13145e489, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056107, encodeId=0a0a205610e64, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Nov 22 18:51:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801178, encodeId=d56618011e855, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811285, encodeId=fb0a181128505, content=<a href='/topic/show?id=92ea8e68308' target=_blank style='color:#2F92EE;'>#药物分子机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87683, encryptionId=92ea8e68308, topicName=药物分子机制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 26 20:51:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308185, encodeId=3f55130818536, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314574, encodeId=9f4e13145e489, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056107, encodeId=0a0a205610e64, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Nov 22 18:51:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801178, encodeId=d56618011e855, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811285, encodeId=fb0a181128505, content=<a href='/topic/show?id=92ea8e68308' target=_blank style='color:#2F92EE;'>#药物分子机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87683, encryptionId=92ea8e68308, topicName=药物分子机制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 26 20:51:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308185, encodeId=3f55130818536, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314574, encodeId=9f4e13145e489, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056107, encodeId=0a0a205610e64, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Nov 22 18:51:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801178, encodeId=d56618011e855, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Sep 27 05:51:00 CST 2012, time=2012-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811285, encodeId=fb0a181128505, content=<a href='/topic/show?id=92ea8e68308' target=_blank style='color:#2F92EE;'>#药物分子机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87683, encryptionId=92ea8e68308, topicName=药物分子机制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuNQXObUwZmFG3VcZa2uhFq27sY7vfTowUhQCgRj2bj1odUibMF4sFXpuRLf6IE5t5yGVDSiaOoOcQ/132, createdBy=1e622500088, createdName=ms1065684921169360, createdTime=Fri Apr 26 20:51:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308185, encodeId=3f55130818536, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314574, encodeId=9f4e13145e489, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 02 01:51:00 CST 2012, time=2012-08-02, status=1, ipAttribution=)]
    2012-08-02 sunylz
Baidu
map
Baidu
map
Baidu
map